BioCentury
ARTICLE | Financial News

Cardiome raises C$15 million in follow-on

February 21, 2014 12:39 AM UTC

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) raised C$15 million ($13.7 million) through the sale of 1.5 million shares at C$10 in a follow-on underwritten by Canaccord and other undisclosed banks. Shareholder CarCor Investment Holdings raised C$15 million through the sale of 1.5 million shares in a concurrent secondary offering. Cardiome has two products marketed outside of the U.S.: IV Brinavess vernakalant for rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm, and Aggrastat tirofiban for acute coronary syndrome (ACS). Brinavess is a mixed ion channel antagonist, and Aggrastat is a non-peptide GPIIb/IIIa (CD41/CD61) antagonist. ...